A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
Recruiting · NCT06833853 · Observational (researchers observe without assigning treatment) · Lead sponsor: Menarini Silicon Biosystems, INC
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA/RNA (cfDNA/RNA) analysis.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease.
- HR+/HER2 negative or triple negative (TN) subjects prior to starting first line therapy or beyond in the metastatic setting.
- R HER2+ subjects prior to starting second line therapy or beyond in the metastatic setting.
- Subject must have the CTC HER2, ER, PD-L1, and cfDNA/RNA tests ordered during routine patient care.
- Age \> 18 years.
Exclusion criteria
- Participant is pregnant.
- Inability to provide blood samples based on the judgment of the treating physician.
Where it is running
1 location listed across 1 US state.
- UPMC Magee Womens Hospital - Pittsburgh, Pennsylvania, United States